Cancer type

Melanoma / skin

Cutaneous melanoma updates on ctDNA after resection and during adjuvant therapy.

Jul 11, 2025Melanoma MRD / ctDNA Biomarkers Tumor-informed

CheckMate 915: tumor-informed ctDNA positivity after resection was associated with melanoma recurrence

A Journal for ImmunoTherapy of Cancer analysis published July 11, 2025, of adjuvant nivolumab with or without ipilimumab in resected stage III or IV melanoma found tumor-informed ctDNA at baseline in 16.2% of tested patients, and ctDNA positivity at baseline or on treatment was associated with recurrence (HR 1.97; 95% CI 1.57 to 2.46).

Journal for ImmunoTherapy of Cancer

November 2024Melanoma MRD / ctDNA Trials

DETECTION-2 is testing ctDNA monitoring against immediate adjuvant therapy in resected stage II and IIIA melanoma

A 2025 methods report describes DETECTION-2 (ISRCTN13695430), a feasibility randomization of patients with resected stage IIB, IIC, or IIIA melanoma to standard adjuvant therapy or to ctDNA monitoring with treatment if ctDNA is detected, and states that eight UK sites opened between November 27 and December 23, 2024.

EJC Skin Cancer